Hikma Pharmaceuticals’ (HIK) “Buy” Rating Reiterated at Citigroup

Citigroup reissued their buy rating on shares of Hikma Pharmaceuticals (LON:HIK) in a research note released on Thursday morning,Digital Look reports.

A number of other equities analysts have also weighed in on the company. Jefferies Financial Group upped their target price on Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Berenberg Bank reissued a “buy” rating and issued a GBX 1,800 price target on shares of Hikma Pharmaceuticals in a research report on Tuesday, April 28th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a GBX 195 price target on shares of Hikma Pharmaceuticals in a research note on Monday, June 22nd. Six investment analysts have rated the stock with a Buy rating, According to MarketBeat, Hikma Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of GBX 1,687.

Hikma Pharmaceuticals Trading Up 0.6%

Shares of HIK stock opened at GBX 1,561 on Thursday. The company has a debt-to-equity ratio of 61.84, a quick ratio of 1.27 and a current ratio of 1.82. Hikma Pharmaceuticals has a 52-week low of GBX 1,187 and a 52-week high of GBX 2,052. The firm has a fifty day moving average of GBX 1,492.24 and a 200-day moving average of GBX 1,449.18. The stock has a market cap of £3.28 billion, a price-to-earnings ratio of 8.62, a P/E/G ratio of 2.38 and a beta of 0.65.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.